Download in electronic PDF format for $25

Kalchem International - Chemicals and Compounding Supplies

Search the Complete Journal Archives

Basics of Compounding with Dilutions and Concentrates

Author(s):  Allen Loyd V Jr

Issue:  Jan/Feb 2017 - Volume 21, Number 1
View All Articles in Issue

Abstract:  Pharmacists use various sources for obtaining the active pharmaceutical ingredient for compounding medications. In many cases, it is the pure drug (United States Pharmacopeia, National Formulary, or similar grade); in some cases, it can be a commercial dosage form; and, in some cases, it may be a dilution or concentrate. If the drug is not present at full strength, then adjustments may be necessary to obtain the required quantity of drug. Also, in many cases, it is necessary to use a dilution or a concentrate of a drug due to safety and quality reasons. Presented within this article are new sources of active pharmaceutical ingredients that are now available to aid pharmacists in meeting future United States Pharmacopeia <800> standards. It is critical that the pharmacist be aware of the strength of the drug and any other excipients that may be available.

Related Keywords: Loyd V. Allen, Jr., PhD, RPh, trituration, dilution, concentrates, stock preparations, liothyronine sodium, T3, levothyroxine sodium, T4, thyroid replacement, thyroid disorders, solid dilutions, stablity, liquid dilutions, aqueous concentrates, oil concentrates, sex hormones, sex steroids, estrogens, estrone, E1, estradiol, E2, estriol, E3, progesterone, P4, androgen, testosterone, menopause, hormone replacement therapy, HRT, hormone ratios, calculation aid

Related Categories: EXCIPIENTS, FORMULATIONS, HRT, SUPPORT, QUALITY CONTROL

Printer-Friendly Version

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Basics of Compounding with Dilutions and Concentrates Allen Loyd V Jr Jan/Feb 2017 39-45 Buy
Bioidentical Thyroid Replacement Therapy in Practice: Delivering a Physiologic T4-T3 Ratio for Improved Patient Outcomes with the Listecki-Snyder Protocol Snyder Scott, Listecki Robert E Sep/Oct 2012 376-380 Buy
Liothyronine Sodium (T3) 5-mcg/0.1-mL Transdermal Cream Allen Loyd V Jr Nov/Dec 2008 546 Buy
Liothyronine Sodium (T3) 5-mcg/Hydrocortisone 5-mg Slow-Release Capsules Allen Loyd V Jr Nov/Dec 2008 545 Buy
Liothyronine Sodium (T3) 5-mcg/Selenium 100-mcg Slow-Release Capsules Allen Loyd V Jr Nov/Dec 2008 547 Buy
Liothyronine Sodium (T3) 5-mcg Slow-Release Capsules Allen Loyd V Jr Nov/Dec 2008 548 Buy
Kinetic Analysis of Drug Release from Compounded Slow-release Capsules of Liothyronine Sodium (T3) Bakhteyar Hamid, Cassone Clayton, Kohan Hamed Gilzad, Sani Shabnam N Sep/Oct 2017 418-425 Buy
Thyroid Potency Calculations Stack Bob Jul/Aug 2010 306-309 Buy
Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh Allen Loyd V Jr Nov/Dec 2003 449-450 Buy
Basics of Compounding: Basics of Compounding with Aliquots, Dilutions, and Concentrates Allen Loyd V Jr Nov/Dec 2010 508-510 Buy